Molecular Partners (MOLN) TD Cowen 2nd Annual Radiopharmaceutical Innovation Summit summary

Platform and technology overview

• DARPins are engineered mini-proteins derived from ankyrin repeat proteins, offering small size, high solubility, and deep tissue penetration for radiopharmaceutical applications.

• The platform enables high-affinity, highly specific targeting, with engineering to optimize half-life and minimize kidney retention.

• Surface engineering and half-life extension strategies have improved tumor-to-kidney ratios and overall targeting efficiency.

• DARPins' stability allows for robust manufacturing and repeated application of platform learnings to new targets.

Pipeline and partnerships

• The pipeline includes collaborations with Novartis (two undisclosed targets) and Orano Med (DLL3 and up to two additional programs), plus internal proprietary efforts.

• Orano Med supplies lead-212 and is a 50/50 partner, providing reliable isotope supply and logistics for clinical development.

• The Novartis partnership began in late 2021, with $20M upfront, up to $560M in milestones, and double-digit royalties.

• Internal pipeline targets remain undisclosed, with plans to reveal more in the second half of the year.

Lead clinical candidate (MP0712)

• MP0712 targets DLL3, a validated target in small cell lung cancer, using a DARPin conjugated to lead-212 via a DOTAM chelator.

• Preclinical data show high tumor uptake (30–60%) and favorable tumor-to-kidney ratios, with strong safety and efficacy in mouse models.

• First-in-human studies are planned for 2025, with imaging and dose escalation as initial endpoints.

• The collaboration with Orano Med ensures supply chain reliability and clinical readiness for MP0712.